Glaukos Corporation Stock News

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos shares rose more than 7% in Thursday premarket trading after the company announced US Food and Drug Administration (FDA) approval for iDose TR (travoprost intracameral implant). The iDose TR i

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

Glaukos Corporation (NYSE:GKOS ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Tom Burns - Ch

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Str

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.

Some markets gave up their early gains on Friday but still were higher for the week. Aehr Test Systems expects a strong year in fiscal 2024.